RxDoctor Payments DataLook up a doctor →

Robert Leonardi, MD

Interventional Cardiology · West Columbia, SCNPI 1013182898

Payments from drug & device makers

$880,936in general payments, 2019–2025

Across 801 payments — averaging $1099.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$505K
  • Abbott$159K
  • Edwards Lifesciences$133K
  • Inari Medical, Inc.$72K
  • Medtronic$8K
  • Novartis$931
  • plus $3K from 30 others

What the payments were for

  • Consulting fees$126,09462%
  • Speaking & faculty fees$29,09414%
  • Grants$890%
  • Travel & lodging$34,45117%
  • Food & beverage$13,5767%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$880,936 in reported general payments places this provider in the 95th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$453,789
Medicare patients
1,221
Services billed
8,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban402$371,482
EntrestoSacubitril/Valsartan105$91,840
BrilintaTicagrelor105$53,596
XareltoRivaroxaban33$39,250
MultaqDronedarone Hcl11$24,041
JardianceEmpagliflozin14$13,348
FarxigaDapagliflozin Propanediol11$6,172
Metoprolol Succinate323$4,465
Dofetilide19$4,451
Atorvastatin Calcium310$3,676
Ranolazine ErRanolazine21$3,375
Diltiazem 24hr Er (Cd)Diltiazem Hcl86$3,108
Losartan Potassium253$2,995
Carvedilol363$2,896
Ezetimibe61$2,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$371,482402 claims
NovartisEntresto$931$91,840105 claims
AstraZenecaBrilinta, Farxiga$116$59,768116 claims
Johnson & JohnsonXarelto$42$39,25033 claims
Sanofi-aventis U.S. LLCMultaq$41$24,04111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →